CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
COMPLIANCE UNDER REGULATION 39(3) OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 201509-05-2019
09-05-2019
CAPLIN POINT LABORATORIES LTD. - 524742 - COMPLIANCE CERTIFICATE UNDER REGULATION 40(9) OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 FOR THE HALF YEAR ENDED MARCH 31, 2019.
COMPLIANCE CERTIFICATE UNDER REGULATION 40(9) OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 FOR THE HALF YEAR ENDED MARCH 31, 2019.22-04-2019
Caplin Point Laboratories Ltd - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliance under Regulation 39(3) of SEBI (LODR),201522-04-2019
Caplin Point Laboratories Ltd - 524742 - Compliance Certificate For The Half Year Ended March 31,2019.
Compliance Certificate for the half year ended March 31,2019.19-04-2019
Caplin Point Laboratories Ltd - 524742 - Shareholding for the Period Ended March 31, 2019
Caplin Point Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here18-04-2019
Caplin Point Laboratories Ltd - 524742 - Statement Of Investor Complaints For The Quarter Ended March 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 212131 Name of the Signatory :- Vinod Kumar SDesignation :- Company Secretary and Compliance Officer13-04-2019
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Cessation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015, we wish to inform BSE that Dr Philip Ashok Karunakaran has tendered his resignation from the position of Whole-time Director and from the Board due to health reasons, effective from the close of business working hours on April 10, 2019. The Company wishes to place on record the valuable contributions made by Dr Philip Ashok Karunakaran during his tenure as a Whole-time Director. We further wish to inform that the Company has appointed Mr M Panjatcharam (who was previously the Head of R&D; - Quality at Sun Pharmaceuticals Industries Limited) as a Whole-time Director of Caplin Steriles Limited (Wholly Owned Subsidiary Company) and as Head of Quality, R&D; and Operations for the Company's regulated markets injectable business, including US FDA approved injectable plant and DSIR recognised R&D; Units CP4 & CP 5, which is now Caplin Steriles Limited. Mr. Panjatcharam is an Analytical Chemistry Post Graduate and a Pharma Professional with more than 25 years of experience in various Quality Control, Assurance and R&D; Functions in API, Formulation, Pharma R&D;, Biologics with Strong Exposure on cGMP Requirements & Designing of Product Quality Attributes on Injectables, Ophthalmics, Inhalers, Oncology Products, Potent Molecules and Peptides. He was Involved in many successful regulated inspections of USFDA, EUGMP, MHRA, MCC, TGA, ANVISA and BFRM. His past assignments include Quality leadership roles in Dr.Reddy's Laboratories Limited, Dabur Research Foundation, Aurobindo Pharma Limited etc.11-04-2019
Company news: Caplin Point Laboratories
Caplin Point Laboratories on Monday said its subsidiary has entered into a licence and supply agreement with Baxter Healthcare Corporation for a portf08-04-2019
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
We wish to inform BSE that Caplin Steriles Limited, a Wholly Owned Subsidiary Company of Caplin Point Laboratories Limited, has entered into a license and supply agreement with Baxter Healthcare Corporation for five generic injectable ANDAs.08-04-2019
CAPLIN POINT LABORATORIES LTD. - 524742 - Closure of Trading Window
This is to inform BSE that, the trading window for dealing in the equity shares of the Company will be closed for Promoters, Directors, other Connected Persons and Employees of the Company with immediate effect till 48 (forty eight ) hours after the declaration of Audited Financial Results for the quarter/ year ended March 31,2019, as per the Company's Code of Conduct to regulate, monitor and report trading by insiders adopted by the Board pursuant to SEBI(Prohibition of Insider Trading) Regulations,2015.05-04-2019